• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Joshua Ofman: Early Detection of Cancer Is Vital to the Progression of Oncology Care

Video

GRAIL has generated enormous innovations in oncology care over the past 2 decades and will continue this trend through exploring 1 of oncology’s biggest opportunities, early detection of cancer, said Joshua Ofman, MD, chief of Corporate Strategy and External Affairs at GRAIL Inc.

GRAIL has generated enormous innovations in oncology care over the past 2 decades, and will continue this trend through exploring 1 of oncology’s biggest opportunities, early detection of cancer, said Joshua Ofman, MD, chief of Corporate Strategy and External Affairs at GRAIL Inc.

Transcript

How does GRAIL delineate what works and what doesn’t work when it comes to formulating strategies for improving oncology care?

We've made enormous progress in oncology over the last 2 decades. We've developed novel therapeutics, innovative approaches, and molecular diagnostics are now playing an increasing role in cancer. As we've looked at the opportunities to improve cancer care, early detection of cancer seems to be 1 of the biggest opportunities. So, as we've strategically thought about this new technology that GRAIL’s developed using circulating DNA and evaluating an individual's DNA, that's circulating in the blood to look for cancer signals, the opportunity we saw before us was in early cancer detection. Too many cancers are simply detected too late, where outcomes are poor and that's causing an enormous burden in this country that's both human and economic around cancer. So, by early detection, and providing something simple like a blood test for the broad population of screening eligible patients, we think this can be a game changer for how we could approach cancer control and early cancer detection.

Related Videos
Will Shapiro
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.